Related references
Note: Only part of the references are listed.FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2021)
Precision Medicine in Osteosarcoma: MATCH Trial and Beyond
Elisa Tirtei et al.
CELLS (2021)
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma
Marissa A. Just et al.
PEDIATRIC BLOOD & CANCER (2021)
Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622).
Srivandana Akshintala et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.
Donald Williams Parsons et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome
Xiaonan Zhao et al.
JCO PRECISION ONCOLOGY (2021)
The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead
William E. Evans et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review
Evelina Cardoso et al.
THERAPEUTIC DRUG MONITORING (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
Antoine Italiano et al.
LANCET ONCOLOGY (2020)
Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor
Joanna Robles et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2020)
Characterization of on-target adverse events caused by TRK inhibitor therapy
D. Liu et al.
ANNALS OF ONCOLOGY (2020)
Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.
Kelly C. Goldsmith et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.
Michela Casanova et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
Lu Xie et al.
CANCER MANAGEMENT AND RESEARCH (2020)
IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.
Emanuela Palmerini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).
Johannes H Schulte et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
Kieuhoa T. Vo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups
Elke Pfaff et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier et al.
CANCERS (2020)
Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective
Helen Pearson et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2020)
A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas
Ida Russo et al.
FRONTIERS IN ONCOLOGY (2020)
Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER
F. Duffaud et al.
ANNALS OF ONCOLOGY (2020)
Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial
Aaron R. Weiss et al.
LANCET ONCOLOGY (2020)
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212)
Emily Greengard et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer
Lionel Groussin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Zhichao Tian et al.
FRONTIERS IN ONCOLOGY (2020)
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
Liling Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries
Andres F. Cardona et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2020)
NTRK fusions in osteosarcoma are rare and non-functional events
Baptiste Ameline et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2020)
Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
Olivier Mir et al.
CLINICAL CANCER RESEARCH (2019)
Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity
Ellen Watts et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Winning the RACE: Expanding pediatric cancer drug approvals
David S. Shulman et al.
PEDIATRIC BLOOD & CANCER (2019)
Timing of first-in-child trials of FDA-approved oncology drugs
Dylan Neel et al.
EUROPEAN JOURNAL OF CANCER (2019)
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Lara E. Davis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Breelyn A. Wilky et al.
LANCET ONCOLOGY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeted treatment approaches in refractory germ cell tumors
Laura Galvez-Carvajal et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors
Elaine M. Oberlick et al.
CELL REPORTS (2019)
Phospho-Protein Arrays as Effective Tools for Screening Possible Targets for Kinase Inhibitors and Their Use in Precision Pediatric Oncology
Jakub Neradil et al.
FRONTIERS IN ONCOLOGY (2019)
Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies
Pauline Corbaux et al.
EUROPEAN JOURNAL OF CANCER (2019)
Medulloblastoma in the age of molecular subgroups: a review
Kyle Juraschka et al.
JOURNAL OF NEUROSURGERY-PEDIATRICS (2019)
Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors
Ji Won Lee et al.
PLOS ONE (2019)
Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiology and Therapeutics
Yu-sheng Li et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2019)
TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening
Catherine M. Albert et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Florence Duffaud et al.
LANCET ONCOLOGY (2019)
Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial
Lu Xie et al.
ONCOLOGIST (2019)
Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials
Melissa Vos et al.
ACTA ONCOLOGICA (2019)
Gastrointestinal stromal tumors: a comprehensive review
Trisha M. Parab et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors
Toby Trahair et al.
JCO PRECISION ONCOLOGY (2019)
Pazopanib in advanced soft tissue sarcomas
Alex T. J. Lee et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Consensus and controversies regarding the treatment of rhabdomyosarcoma
Scott C. Borinstein et al.
PEDIATRIC BLOOD & CANCER (2018)
The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients
M. Longue et al.
ANNALS OF ONCOLOGY (2018)
Selective RET kinase inhibition for patients with RET-altered cancers
V. Subbiah et al.
ANNALS OF ONCOLOGY (2018)
Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population
Pei-Wei Huang et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Targeting tumour microenvironment by tyrosine kinase inhibitor
Hor-Yue Tan et al.
MOLECULAR CANCER (2018)
The landscape of genomic alterations across childhood cancers
Susanne N. Groebner et al.
NATURE (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma
John A. Heath et al.
PEDIATRIC BLOOD & CANCER (2018)
Pazopanib therapy for desmoid tumors in adolescent and young adult patients
Laura Agresta et al.
PEDIATRIC BLOOD & CANCER (2018)
Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions
Sogol Mostoufi-Moab et al.
THYROID (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma
Fabio Morandi et al.
ONCOIMMUNOLOGY (2018)
ALK in Neuroblastoma: Biological and Therapeutic Implications
Ricky M. Trigg et al.
CANCERS (2018)
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
Steven G. DuBois et al.
CANCER (2018)
Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN plus etoposide (ETP) plus ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).
Nathalie Gaspar et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
Giselle L. Saulnier Sholler et al.
SCIENTIFIC REPORTS (2018)
Sorafenib for Advanced and Refractory Desmoid Tumors
Mrinal M. Gounder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
Holly L. Pacenta et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma o the ALK inhibitor ceritinib
Jikui Guan et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2018)
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Andrew C. Wood et al.
CLINICAL CANCER RESEARCH (2017)
Precision medicine in pediatric oncology: Lessons learned and next steps
Rajen J. Mody et al.
PEDIATRIC BLOOD & CANCER (2017)
Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study)
Julia C. Chisholm et al.
EUROPEAN JOURNAL OF CANCER (2017)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor
Ziad Hussein et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
Fariba Navid et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study
Yael P. Mosse et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P. S. Perera et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective
Lucas Moreno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions
Pierre Vanden Borre et al.
ONCOLOGIST (2017)
Complete remission of refractory hepatoblastoma after liver transplantation in a child with sorafenib monotherapy: A new hope?
Naresh Shanmugam et al.
PEDIATRIC BLOOD & CANCER (2017)
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon et al.
CANCER DISCOVERY (2017)
A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARCO24 trial results
Steven Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comprehensive Analysis of Hypermutation in Human Cancer
Brittany B. Campbell et al.
CELL (2017)
Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
Roelof W. F. van Leeuwen et al.
CLINICAL PHARMACOKINETICS (2017)
Treatment Pathway of Bone Sarcoma in Children, Adolescents, and Young Adults
Damon R. Reed et al.
CANCER (2017)
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Kateryna Krytska et al.
CLINICAL CANCER RESEARCH (2016)
Receptor tyrosine kinase inhibitors: Are they real tumor killers?
Andreas K. A. Gaumann et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Genetics of anaplastic large cell lymphoma
Yu Zeng et al.
LEUKEMIA & LYMPHOMA (2016)
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma
Nicole R. Infarinato et al.
CANCER DISCOVERY (2016)
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model
Radhika Iyer et al.
CANCER LETTERS (2016)
MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
Wendy Chang et al.
CLINICAL CANCER RESEARCH (2016)
Biology and treatment of renal tumours in childhood
Jesper Brok et al.
EUROPEAN JOURNAL OF CANCER (2016)
Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study
Barbara C. Worst et al.
EUROPEAN JOURNAL OF CANCER (2016)
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward
Joanne P. Lagmay et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy
Thomas Wiesner et al.
PATHOLOGY (2016)
Malignant tumors of the liver in children
Daniel C. Aronson et al.
SEMINARS IN PEDIATRIC SURGERY (2016)
Neuroblastoma
Katherine K. Matthay et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors The Individualized Cancer Therapy (iCat) Study
Marian H. Harris et al.
JAMA ONCOLOGY (2016)
Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis
Angela Bellini et al.
CLINICAL CANCER RESEARCH (2015)
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials
F. Duffaud et al.
EUROPEAN JOURNAL OF CANCER (2015)
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Rajen J. Mody et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Giovanni Grignani et al.
LANCET ONCOLOGY (2015)
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group
AeRang Kim et al.
PEDIATRIC BLOOD & CANCER (2015)
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele et al.
CANCER DISCOVERY (2015)
Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine
Vivek Subbiah et al.
ONCOTARGET (2015)
Detection of tumor ALK status in neuroblastoma patients using peripheral blood
Valerie Combaret et al.
CANCER MEDICINE (2015)
Phase II Study of Cixutumumab in Combination With Temsirolimus in Pediatric Patients and Young Adults With Recurrent or Refractory Sarcoma: A Report From the Children's Oncology Group
Lars M. Wagner et al.
PEDIATRIC BLOOD & CANCER (2015)
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Aria Vaishnavi et al.
CANCER DISCOVERY (2015)
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
B. Kasper et al.
ANNALS OF ONCOLOGY (2014)
Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
Emmy D. G. Fleuren et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
A. B. Suttle et al.
BRITISH JOURNAL OF CANCER (2014)
FGF Receptors: Cancer Biology and Therapeutics
Masaru Katoh et al.
MEDICINAL RESEARCH REVIEWS (2014)
RET revisited: expanding the oncogenic portfolio
Lois M. Mulligan
NATURE REVIEWS CANCER (2014)
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
Ymera Pignochino et al.
CLINICAL CANCER RESEARCH (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting developmental pathways in children with cancer: what price success?
Lia Gore et al.
LANCET ONCOLOGY (2013)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh et al.
NATURE GENETICS (2013)
The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib
Wei-feng Mao et al.
ACTA PHARMACOLOGICA SINICA (2012)
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
G. Grignani et al.
ANNALS OF ONCOLOGY (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Christine M. Lovly et al.
CANCER RESEARCH (2011)
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
Shu Tian et al.
CANCER SCIENCE (2011)
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A. Becker et al.
EUROPEAN JOURNAL OF CANCER (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Scott C. Bresler et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Angiogenesis and Vascular Targeting in Ewing Sarcoma A Review of Preclinical and Clinical Data
Steven G. DuBois et al.
CANCER (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
Paul Hamberg et al.
ONCOLOGIST (2010)
The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma
Raushan T. Kurmasheva et al.
CANCER RESEARCH (2009)
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models
James G. Taylor et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors
Wayne L. Furman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Robert G. Maki et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Small molecule tyrosine kinase inhibitors:: Potential role in pediatric malignant solid tumors
Jochen Roesler et al.
CURRENT CANCER DRUG TARGETS (2008)
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A children's oncology group study
Julia L. Glade Bender et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor
Philip A. Harris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study
Mason Bond et al.
PEDIATRIC BLOOD & CANCER (2008)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Tyrosine kinase inhibitors in pediatric malignancies
Jeffrey M. Skolnik et al.
CANCER INVESTIGATION (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Dai Fukumura et al.
MICROVASCULAR RESEARCH (2007)
Mechanisms of Disease: oncogene addiction - a rationale for molecular targeting in cancer therapy
I. Bernard Weinstein et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
B Lawrence et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
